期刊文献+

MicroRNA100在对阿霉素耐药的乳腺癌细胞中的表达 被引量:3

MicroRNA100 on Adriamycin Resistance Expression in Breast Cancer Cells
下载PDF
导出
摘要 目的:观察Micro RNA100(mi R-100)在对阿霉素耐药的乳腺癌细胞的表达情况。方法:培养并传代人乳腺癌阿霉素耐药细胞(MCF7/ADM)以及人乳腺癌细胞(MCF7),提取细胞中的micro RNA,使用Real-time RT-PCR对mi R-100的表达水平进行相对定量分析,并采用非配对t检验对两种细胞中mi R-100的表达情况进行统计分析。结果:在正常人乳腺癌细胞中,mi R-100表达量非常少,但在MCF7/ADM细胞中mi R-100表达明显上调,与MCF7细胞比较,差异具有统计学意义。结论:mi R-100在对阿霉素耐药的人乳腺癌细胞中呈现高表达,有机会作为一个乳腺癌耐药潜在的治疗、诊断靶点。 objective:Observe Micro RNA100(mi R-100) on adriamycin resistance expression of breast cancer cells.Methods:develop and extend the adriamycin resistance of breast cancer cells(MCF7 / ADM) and human breast cancer cell(MCF7),extract the mirnas in the cell,use the Real-time rt-pcr expression levels of mi R-100 relative quantitative analysis,and using the paired t test for two kinds of cells in the expression of mi R-100 cases were analyzed.Results:in normal human breast cancer cells,the expression of mi R-100 quantity is less,but mi R-100 in MCF7 / ADM cells express raised obviously,compared with MCF7 cells,the difference is statistically significant.Conclusion:mi R-100 in adriamycin resistance show high expression in human breast cancer cells,have the opportunity to as a potential treatment of breast cancer drug resistance,diagnostic targets.
出处 《黑龙江医药》 CAS 2016年第2期223-225,共3页 Heilongjiang Medicine journal
基金 广东省医学科研基金项目:(B2016070)
关键词 MICRO RNA100 阿霉素 乳腺癌 耐药 Micro RNA100 doxorubicin breast cancer drug resistance
  • 相关文献

参考文献11

二级参考文献86

  • 1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[ J]. CA Cancer J Clin, 2010, 60(5) : 277 -300.
  • 2Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis [ J]. Clin Pharmacol, 2005, 45 (8) : 872 - 877.
  • 3Reya T, Morrison SJ, Clarke MF, et al. Stem ceils, cancer, and cancer stem cells[J]. Nature, 2001,414(6859) : 105 -111.
  • 4Charafe - Jauffret E, Monville F, Ginestier C, et al. Cancer stem ceils in breast : current opinion and future challenges [ J ]. Pathobiol- ogy, 2008, 75 (2) : 75 - 84.
  • 5Kakarala M, Wicha MS. Implications of the cancer stem - cell hy- pothesis for breast cancer prevention and therapy [J].Clin Oncol, 2008, 26(17) : 2813 -2820.
  • 6Baguley BC. Multidrug resistance in cancer[ J]. Methods Mol Biol, 2010, 596 : 1 - 14.
  • 7Ginestier C, Hur MH, Charafe -Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome [ J ]. Cell Stem Cell, 2007, 1 ( 5 ) : 555 - 567.
  • 8Morimoto K, Kim S J, Tanei T,et al. Stem cell marker aldehyde de- hydrogenase 1 -positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression[J]. Cancer Sci, 2009, 100(6) : 1062 - 1068.
  • 9Charafe- Jauffret E, Ginesticr C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capac- ity and a distinct molecular signature [ J ]. Cancer Res, 2009,69 (4) : 1302 - 1313.
  • 10Korkaya H, Paulson A, Iovino F,et al. HER2 regulates the mam- mary stern/progenitor cell population driving tumorigenesis and in- vasion[J]. Oncogene, 2008, 27(47): 6120-6130.

共引文献32

同被引文献26

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部